Incident cancer risk after the start of aspirin use: Results from a Dutch population-based cohort study of low dose aspirin users

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 157-165

  Hollestein, Loes M ^a   Van Herk Sukel, Myrthe P P ^b   Ruiter, Rikje ^a   De Vries, Esther ^a,c   Mathijssen, Ron H J ^a   Wiemer, Erik A C ^a   Stijnen, Theo ^d   Coebergh, Jan Willem W ^a,c   Lemmens, Valery E P P ^a,c   Herings, Ron M C ^a,b   Stricker, Bruno H C ^a,b,e   Nijsten, Tamar ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c Department of Epidemiology Erasmus MC University Medical Center ^*  (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Drug Safety Unit   (Netherlands)

Author keywords

aspirin; cancer; chemoprevention; epidemiology; population based

Indexed keywords

ASPIRIN; CANCER; CHEMOPREVENTION; EPIDEMIOLOGY; POPULATION-BASED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84899426836     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28634     Document Type: Article

References (31)

1. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
2. Algra AM, Rothwell PM,. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-27.
3. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
4. Jacobs EJ, Newton CC, Gapstur SM, et al. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012; 104: 1208-17.
5. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO record linkage system. Eur J Cancer 2010; 46: 395-404.
6. Eindhoven Cancer Registry. Avalable at: < http://www.ikz.nl/page.php? id=2898 &nav-id=160>. (Accessed: 27 April 2013).
7. Schouten LJ, Hoppener P, van den Brandt PA, et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369-76.
8. Dutch federation of Biomedical Scientific Societies, Code of conduct for health research, 2004.
9. PHARMO institute for drug outcome research. Available at: < http://www.pharmo.nl/ >. (Accessed: 15 May 2013).
10. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
11. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55: 51-62.
12. Joosse A, Koomen ER, Casparie MK, et al. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129: 2620-7.
13. Stricker BH, Stijnen T,. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245-51.
14. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.
15. Walter RB, Milano F, Brasky TM, et al. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective vitamins and lifestyle (VITAL) study. J Clin Oncol 2011; 29: 2424-31.
16. Curiel-Lewandrowski C, Nijsten T, Gomez ML, et al. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 131: 1460-8.
17. Jeter JM, Han J, Martinez ME, et al. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' health study. Cancer Causes Control 2012; 23: 1451-61.
18. Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118: 4768-76.
19. Nunes AP, Lapane KL, Weinstock MA, et al. Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf 2011; 20: 922-9.
20. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359: 2567-78.
21. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-7.
22. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
23. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85.
24. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-16.
25. Antithrombothic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
26. Clinicaltrials.gov. Available at: < http://www.clinicaltrials.gov/ >. (Accessed: 21 May 2013).
27. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-606.
28. Suissa S,. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9.
29. Beyersmann J, Gastmeier P, Wolkewitz M, et al. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008; 61: 1216-21.
30. Renehan AG,. Insulin analogues and cancer risk: the emergence of second-generation studies. Diabetologia 2012; 55: 7-9.
31. Yood MU, Campbell UB, Rothman KJ, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 2007; 16: 961-8.